Pre-activated freezing shock neutrophil nanoparticle with anti-inflammatory and anti-oxidation functions as well as preparation method and application of pre-activated freezing shock neutrophil nanoparticle

Pre-activate cryoshock neutrophil nanoparticles combined with catalase through TNF-α, which solves the problem of difficulty in targeting proinflammatory cytokines and reducing ROS in the prior art, and achieves the sepsis and novel coronavirus Effective treatment of infection and skin wounds significantly improves the therapeutic effect and wound healing speed.

CN119033727APending Publication Date: 2024-11-29NINGXIA MEDICAL UNIV +3
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410933370.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-12
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

In the treatment of diseases such as sepsis, novel coronavirus infection and skin wounds, it is difficult to simultaneously target proinflammatory cytokines and reduce ROS levels, resulting in limited efficacy.

Method used

Using TNF-α pre-activated cryoshock neutrophil nanoparticles loaded with catalase, pre-activated neutrophils surface expressing more proinflammatory cytokine receptors and chemokine receptors, and combining with ROS, realizes anti-inflammatory and antioxidant functions.

Benefits of technology

Significantly reduce the expression of proinflammatory cytokines, clear ROS, improve treatment effect, significantly reduce inflammatory damage, promote wound healing, and significantly reduce the mortality rate of COVID-19 mice.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119033727A_ABST
    Figure CN119033727A_ABST
Patent Text Reader

Abstract

The invention discloses a pre-activated frozen shock neutrophil nanoparticle with anti-inflammatory and anti-oxidation functions as well as a preparation method and application thereof. TNF-alpha pre-activated frozen shock neutrophil is used as a carrier, and catalase is loaded. The TNF-alpha pre-activated cryoshock neutrophile granulocyte provided by the invention eliminates the inherent inflammatory effect of the neutrophile granulocyte, and retains the complete cell structure, functional receptor and drug delivery capacity at the same time. In mouse sepsis, novel coronavirus infection and skin wound models, the frozen shock neutrophile granulocyte accurately targets inflammatory injury tissues through different ways and resides for a long time, and meanwhile, the frozen shock neutrophile granulocyte can neutralize proinflammatory cytokines in a broad spectrum and effectively remove active oxygen. After treatment, inflammatory injury is obviously relieved, the survival time of mice is prolonged, and wounds are quickly healed. The method based on autologous cells avoids the potential risk of immunological rejection, and provides a huge prospect for clinical transformation.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The patent of this invention relates to the field of biomedicine technology, and more specifically, to a pre-activated cryo-shock neutrophil nanoparticle with anti-inflammatory and antioxidant functions, and a preparation method and application thereof. Background Art

[0002] Sepsis is a complex, life-threatening disease characterized by an unregulated host inflammatory response to infection, resulting in high morbidity and mortality. More precisely, it is a systemic inflammatory response syndrome that exhibits immune overactivation, which may lead to the occurrence of a "cytokine storm" in critical situations. At the same time, it is often accompanied by dysregulation of oxidative stress, excessive production of reactive oxygen species (ROS) and reactive nitrogen species, leading to tissue damage and subsequent development of multiple organ dysfunction syndrome. Therefore, inhibiting the overactivation of the immune response and improving oxidative stress are important strategies for the treatment of sepsis. However, to date, the efficacy of sepsis interventions has been very limited, and the mortality rate of patients receiving treatment remains as high as 50%. Although researchers have conducted hundreds of clinical trials on key candidate drugs for sepsis, only a few drugs have shown a modest improvement in the prognosis of patients with sepsis. An important reason is that sepsis is a highly complex syndrome with a complex pathogenesis involving a large number of proinflammatory cytokines (IL-1β, IL-6, TNF-α, INF-γ, etc.), as well as the interaction between proinflammatory cytokines and ROS. Therefore, drugs or therapies targeting only one or a few specific factors are not sufficient to completely cure the disease. Therefore, it is urgent to develop anti-inflammatory and antioxidant therapeutic strategies that can simultaneously target proinflammatory cytokines and ROS to effectively treat sepsis and improve its prognosis.

[0003] On the other hand, Coronavirus disease 2019 (COVID-19) is a fatal pneumonia caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although the morbidity, severity, and mortality of COVID-19 have been greatly reduced due to the mutation and reduced toxicity of SARS-CoV-2, it still has the potential to cause severe pneumonia and even death. At present, in addition to supportive treatment, the main treatments for COVID-19 include antiviral drugs, immunomodulators, neutralizing antibodies, etc., but their effectiveness needs to be further improved. Similar to the pathophysiological process of sepsis and other inflammatory diseases, SARS-CoV-2-induced pneumonia is characterized by a large infiltration of immune cells in the lung tissue, accompanied by a large release of various proinflammatory cytokines (such as IL-6, TNF-α, and INF-γ) and excessive accumulation of ROS. Considering the complex network and cascade interactions between different proinflammatory cytokines and between proinflammatory cytokines and ROS, the broad-spectrum clearance of these harmful factors may help alleviate the hyperinflammatory state of lung tissue and make effective treatment of COVID-19 possible.

[0004] In addition, the progression of skin wounds also involves inflammation-related reactions and a variety of proinflammatory cytokines and ROS. Due to the involvement of multiple types of cells and active ingredients, skin wound healing is often one of the most complex biological processes and can be divided into four overlapping (but well-defined) stages: hemostasis, inflammation, proliferation, and remodeling. Factors such as bacterial infection often cause severe wound inflammation, leading to the secretion of a large number of proinflammatory cytokines (IL-1β, IL-6, TNF-α) and the production of ROS, which prolongs the wound healing time. Therefore, effective and broad-spectrum removal of proinflammatory cytokines and ROS from the wound microenvironment is expected to accelerate the transition from the inflammatory phase to the proliferation and remodeling phase, thereby promoting rapid wound healing.

[0005] Polymorphonuclear neutrophils (PMNs) are the main immune cells in the blood, accounting for 50-70% of the total white blood cells. Since PMNs carry a variety of chemokine receptors (such as CCR2 and CXCR2) and proinflammatory cytokine receptors (including IL-1R and TNF-αR) on their cell membranes, biomimetic nanoparticles prepared from PMN membranes can achieve precise targeting of inflammatory lesions and neutralize a wide range of proinflammatory cytokines. Considering that blood is the most easily available sample in clinical practice and it is also simple to separate PMNs from blood by gradient centrifugation, coupled with the high content of neutrophils and their potential broad-spectrum anti-inflammatory properties, the use of autologous neutrophils as raw materials to treat inflammatory diseases has great practical application potential. However, living PMNs have an inherent tendency to release proinflammatory cytokines and promote inflammatory infiltration, and direct application of living PMNs cannot achieve a broad-spectrum anti-inflammatory effect. Patent CN 115637254 A discloses a novel freezing shock technology to prepare neutrophils. Under the premise of achieving neutrophil death (loss of inflammatory infiltration and inflammatory cytokine release function), the integrity of its cell membrane protein receptors is retained, so that it can effectively adsorb and neutralize a variety of inflammatory cytokines and improve tissue and organ damage caused by excessive inflammation. However, the content of pro-inflammatory cytokine receptors and chemokine receptors on its membrane surface is low, and its ability to bind to pro-inflammatory cytokines needs to be improved to enhance the therapeutic effect in diseases that may produce cytokine storms (such as sepsis and new coronavirus infection). In addition, as mentioned above, in the treatment of diseases such as sepsis, new coronavirus infection, and skin wounds, anti-inflammatory and anti-oxidation must be simultaneously performed to effectively alleviate the high inflammatory state. Therefore, it is necessary to develop a nanoparticle that can better neutralize pro-inflammatory cytokines, target lesions, reduce ROS levels, and has anti-inflammatory and antioxidant functions to achieve effective treatment of diseases such as sepsis, new coronavirus infection, and skin wounds. Summary of the invention

[0006] The purpose of the present invention is to overcome the above-mentioned defects and deficiencies in the prior art and to provide a pre-activated cryo-shock neutrophil having both anti-inflammatory and anti-oxidative functions.

[0007] The second object of the present invention is to provide a method for preparing the cryo-shocked neutrophils.

[0008] The third object of the present invention is to provide the application of the cryo-shocked neutrophils.

[0009] The above-mentioned object of the present invention is achieved through the following technical solutions: The present invention first provides a pre-activated cryo-shocked neutrophil nanoparticle with both anti-inflammatory and antioxidant functions. The pre-activated cryo-shocked neutrophil nanoparticle is named Cat@P-CD-PMNs. The pre-activated cryo-shocked neutrophil nanoparticle uses TNF-α pre-activated cryo-shocked neutrophils (P-CD-PMNs) as a carrier and is loaded with catalase (Cat). The TNF-α pre-activated cryo-shocked neutrophils use TNF-α pre-activated neutrophils as raw materials and are prepared using the novel cryo-shock technology disclosed in CN 115637254 A.

[0010] The nanoparticles Cat@P-CD-PMNs provided by the present invention are obtained by loading catalase with TNF-α pre-activated frozen shock neutrophils as dead cell carriers. Frozen shock neutrophils eliminate the inherent inflammatory effects of neutrophils, while retaining the complete cell structure, functional receptors and drug delivery capabilities. By pre-activating neutrophils with TNF-α, more pro-inflammatory cytokine receptors and chemokine receptors can be expressed on the cell surface of neutrophils, so that after subsequent freezing shock, pro-inflammatory cytokines can be better neutralized and targeted to lesions; further, by loading catalase, TNF-α pre-activated frozen shock neutrophils can bind to ROS, while exerting anti-inflammatory and antioxidant functions, and more effectively treating inflammatory diseases.

[0011] The present invention also provides a method for preparing the pre-activated cryo-shock neutrophil nanoparticles, comprising the following steps: S1. Obtain neutrophils; S2. Stimulate neutrophils with TNF-α to obtain pre-activated neutrophils; S3. performing cryo-shock on the cryo-fluid containing pre-activated neutrophils to obtain TNF-α pre-activated cryo-shock neutrophils; S4. The TNF-α pre-activated cryo-shocked neutrophils are co-incubated with a catalase solution to obtain TNF-α pre-activated cryo-shocked neutrophil nanoparticles loaded with catalase, i.e., the pre-activated cryo-shocked neutrophil nanoparticles having anti-inflammatory and antioxidant functions.

[0012] Furthermore, the TNF-α stimulation of neutrophils in step S2 is to stimulate neutrophils with recombinant human TNF-α at 36 to 38° C. for 1 to 3 hours.

[0013] Preferably, recombinant human TNF-α is used to stimulate neutrophils at 37° C. for 2 hours.

[0014] Furthermore, in step S1, neutrophils are obtained by using a neutrophil extraction kit through gradient centrifugation separation.

[0015] Preferably, the neutrophils are derived from autologous cell components, with sufficient raw materials and no risk of immune rejection.

[0016] Furthermore, the freezing shock in step S3 is precooling at -75 to -85°C for 15 to 25 minutes and then freezing to death with liquid nitrogen and resuscitation.

[0017] Preferably, the precooling in step S3 is precooling at -80°C for 20 min.

[0018] Preferably, the freezing by liquid nitrogen in step S3 is performed by immersing in liquid nitrogen for 6 to 12 hours.

[0019] Furthermore, the concentration of catalase in the pre-activated frozen shock neutrophil nanoparticles in step S4 is 30 μg / cell. At this concentration, the loading efficiency is about 75%, which is much higher than the cell carriers reported previously.

[0020] The present invention's research shows that in the treatment of sepsis, the above-mentioned nanoparticles can target inflammatory lesions, significantly reduce the expression of proinflammatory cytokines, and effectively remove almost all ROS, which fully demonstrates the targeting effect, broad-spectrum anti-inflammatory effect, and antioxidant effect of the nanoparticles; in the treatment of novel coronavirus infection, the nanoparticles can significantly reduce the concentration of proinflammatory cytokines in lung tissue, significantly inhibit the accumulation of ROS in lung tissue, and significantly reduce the mortality rate of COVID-19 mice, which fully demonstrates the broad-spectrum anti-inflammatory effect, antioxidant effect and overall therapeutic effect of the nanoparticles; in the treatment of skin wounds, the nanoparticles can significantly increase the wound repair rate, remove a large amount of ROS in wound tissue, and significantly reduce tissue necrosis and inflammatory infiltration, which fully demonstrates the ability of the nanoparticles to promote wound healing, antioxidant effect, and wound repair effect.

[0021] The TNF-α pre-activated cryo-shock neutrophil nanoparticles provided by the present invention eliminate the inherent inflammatory effects of neutrophils while retaining intact cell structures, functional receptors and drug delivery capabilities. In mouse sepsis, COVID-19 and skin wound models, the cryo-shock neutrophils accurately target inflammatory damaged tissues through different pathways and reside for a long time, while also neutralizing pro-inflammatory cytokines in a broad spectrum and effectively removing reactive oxygen species. After treatment, inflammatory damage was significantly reduced, mouse survival time was prolonged, and wound healing was rapid.

[0022] Therefore, the present invention also provides the use of the above-mentioned pre-activated cryo-shock neutrophil nanoparticles with anti-inflammatory and antioxidant functions in the preparation of therapeutic drugs for diseases that require simultaneous anti-inflammatory and antioxidant treatments.

[0023] Furthermore, the disease is sepsis, novel coronavirus infection or skin wound.

[0024] The invention also provides an anti-inflammatory and anti-oxidation preparation containing the pre-activated cryo-shocked neutrophils with anti-inflammatory and anti-oxidation functions.

[0025] Furthermore, pharmaceutically acceptable excipients are also included.

[0026] Compared with the prior art, the present invention has the following beneficial effects: The present invention provides a pre-activated cryo-shock neutrophil nanoparticle with anti-inflammatory and antioxidant functions, which is obtained by loading catalase on TNF-α pre-activated cryo-shock neutrophils as dead cell carriers. By pre-activating neutrophils with TNF-α, more pro-inflammatory cytokine receptors and chemokine receptors can be expressed on the cell surface of neutrophils, so that after subsequent cryo-shock, the pro-inflammatory cytokines can be better neutralized and targeted to the lesions; further, by loading catalase, the TNF-α pre-activated cryo-shock neutrophils can be combined with ROS, and at the same time, the anti-inflammatory and antioxidant functions can be exerted, which can achieve effective treatment of diseases such as sepsis, new coronavirus infection, and skin wounds. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] Figure 1 The preparation process of pre-activated autologous cryo-shocked neutrophil nanoparticles (Cat@P-CD-PMNs) with anti-inflammatory and antioxidant functions.

[0028] Figure 2 This is the scanning electron microscope image of Cat@P-CD-PMNs.

[0029] Figure 3 The expression of proinflammatory cytokine receptors (IL-6, IL-1β, IFN-γ, TNF-α, IL-12 receptor) and chemokine receptor (CXCR2) after PMNs pre-activation.

[0030] Figure 4 Confocal images of P-CD-PMNs loaded with catalase ( Figure 4 A) and the hydrogen peroxide scavenging effect of Cat@P-CD-PMNs in vitro ( Figure 4 B) and the cell protection effect under high concentration hydrogen peroxide exposure ( Figure 4 C).

[0031] Figure 5 The binding ability of Cat@P-CD-PMNs to different pro-inflammatory cytokines (TNF-α, IFN-γ, IL-6, IL-1β) Figure 5 A-5D) and the binding ability of Cat@P-CD-PMNs and anti-inflammatory cytokines (IL-4 and IL-10) ( Figure 5 E. Figure 5 F).

[0032] Figure 6 Schematic diagram of the transwell migration experiment of Cat@P-CD-PMNs ( Figure 6 A) and the results ( Figure 6 B).

[0033] Figure 7 The targeting ability and retention effect of Cat@P-CD-PMNs on inflamed organs in a mouse model of sepsis ( Figure 7 A. Figure 7 B) and the levels of pro-inflammatory cytokines in the lung tissue of mice after treatment ( Figure 7 C-7F) and ROS levels in liver and lung tissues ( Figure 7 G-7I).

[0034] Figure 8 In order to replace the mouse model of COVID-19, the levels of various pro-inflammatory cytokines (IFN-γ, IL-1β, IL-6 and TNF-α) in lung tissue after Cat@P-CD-PMNs treatment ( Figure 8 A-8D) and ROS levels ( Figure 8 E) and the mortality rate of mice after treatment ( Figure 8 F).

[0035] Fig. 9 Figure 2 is the change of skin wound area after Cat@P-CD-PMNs treatment in the skin wound mouse model ( Fig. 9 A. Fig. 9 B) and ROS levels in skin wounds ( Fig. 9 C) and H&E staining results ( Fig. 9 D). DETAILED DESCRIPTION

[0036] The following will combine the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0037] Example 1 Preparation of anti-inflammatory and antioxidant pre-activated cryo-shock neutrophils Cat@P-CD-PMNs The preparation steps of human Cat@P-CD-PMNs are as follows: S1. Use the Neutrophil Extraction Kit (P9040, Solebao) to separate and collect fresh self-source PMNs by gradient centrifugation: First, add 4 mL of reagent A to the centrifuge tube, then carefully superimpose 2 mL of reagent C on reagent A to form a gradient interface, and spread the fresh anticoagulated blood above the liquid surface of liquid C to keep the interface between the two liquid surfaces clear. Then centrifuge at 500-1000g for 20-30 min. Subsequently, carefully pipette the neutrophils between reagent C and reagent A and in reagent A into a 15 mL clean centrifuge tube, and add 10 mL of PBS or cell washing solution to wash the cells twice; S2. To obtain pre-activated PMNs (P-Live PMNs), 50 ng mL −1 Neutrophils were stimulated with recombinant human TNF-α (CHAMOT) at 37°C for 2 h (activated within 16 h after blood collection), and the activated cells were washed with PBS. PMNs and P-Live PMNs were then centrifuged at 250 g for 3 min, suspended in universal serotype non-programmed freezing buffer, and the cell density was adjusted to 1 × 10 6 ~1×10 7 mL −1 The culture medium containing cells was precooled at -80°C for 20 min and then immersed in liquid nitrogen for 12 h for subsequent use; S3. Before use, thaw the cells stored in liquid nitrogen at 37°C and centrifuge at 250 g for 3 min. After washing with PBS solution (pH 7.4), remove the supernatant and collect pre-activated cryo-shock neutrophils (P-CD-PMNs). In the same way, if TNF-α is not added, unactivated cryo-shock neutrophils (CD-PMNs) can be prepared; S4. P-CD-PMNs were suspended in PBS solution containing catalase (2 mg ml -1 After culturing for 2 hours, the culture medium was centrifuged at 300 g for 5 min, and the supernatant was removed to obtain Cat@P-CD-PMNs.

[0038] Example 2 Performance Characterization of Cat@P-CD-PMNs 1. Scanning electron microscopy (SEM): The SEM images show the morphology of PMN, CD-PMN, P-CD-PMN and Cat@P-CD-PMN. The results are as follows: Figure 2As shown in the figure, after freezing to death, the cell surface shrank, the cell volume decreased, and the diameter was 3-6 μm. At the same time, some small holes appeared on the surface of CD-PMN and P-CD-PMN, indicating that their cell membrane permeability increased, which was conducive to the loading of drugs into them. In addition, the size and morphology of Cat@P-CD-PMNs were almost the same as those of P-CD-PMNs, indicating that after loading catalase, the inflammatory targeting and anti-inflammatory properties of P-CD-PMNs would be retained.

[0039] 2. Real-time fluorescence quantitative PCR (RT-qPCR): RT-qPCR shows the expression levels of pro-inflammatory cytokine receptors (IL-6, IL-1β, IFN-γ, TNF-α and IL-12 receptor) and chemokine receptor (CXCR2) in cells, such as Figure 3 As shown in A, P-Live PMNs expressed more pro-inflammatory cytokine receptors and chemokine receptors at the mRNA level compared with PMNs. In addition, the expression of these receptors on PMNs was higher than that on peripheral blood mononuclear cells (PBMCs) isolated from the same batch of healthy human blood, suggesting that CD-PMNs may be more suitable for targeted anti-inflammatory therapy of inflammatory diseases than "freeze-shocked" PBMCs.

[0040] 3. Western blot (WB): Immunoblotting of cell surface cytokine receptors shows that the cytokine receptor protein components of cells still exist after freezing, such as Figure 3 As shown in B, P-Live PMNs showed higher levels of pro-inflammatory cytokine receptors (IL-1R1, IL-6R, and TNFR) and chemokine receptors (CD18 and CXCR2) under the stimulation of TNF-α. The expression levels of these functional receptors on P-CD-PMNs were also significantly higher than those on CD-PMNs, indicating that P-CD-PMNs have stronger broad-spectrum anti-inflammatory and inflammatory chemotactic abilities. In addition, the protein expression of these receptors on PMNs was significantly higher than that on PBMCs, which was consistent with the results of RT-qPCR, strongly proving that P-CD-PMNs have greater potential for the treatment of inflammatory diseases than pre-stimulated cryo-shocked PBMCs.

[0041] 4. Confocal imaging: P-CD-PMNs were incubated with catalase (labeled with FITC) at room temperature for 30 min and then confocal imaging was performed. Figure 4As shown in A, a large amount of catalase quickly penetrated the cell membrane of P-CD-PMNs (labeled with DiI) and entered the cytoplasm, indicating that P-CD-PMNs is a special dead cell carrier with extremely strong drug loading capacity. It is worth noting that when the concentration of catalase is 30μg / cell, the loading efficiency in Cat@P-CD-PMNs is about 75%, which is much higher than other reported cell carriers.

[0042] 5. Antioxidant effect of Cat@P-CD-PMNs: Cat@P-CD-PMNs showed significant hydrogen peroxide scavenging ability in vitro ( Figure 4 B), and significantly inhibited the cell death (L929 cell line) exposed to high concentrations of hydrogen peroxide ( Figure 4 C), demonstrating its powerful antioxidant effect.

[0043] 6. Anti-inflammatory effect of Cat@P-CD-PMNs: Cat@P-CD-PMNs were incubated with different pro-inflammatory cytokines (TNF-α, IFN-γ, IL-6, IL-1β) and anti-inflammatory cytokines (IL-4 and IL-10) at 37°C for 2 h. After centrifugation, the remaining cytokine levels in the supernatant were determined by enzyme-linked immunosorbent assay. The results are shown in Figure 5 Cat@P-CD-PMNs exhibited typical concentration-dependent pro-inflammatory cytokine neutralization ability, effectively removing IL-1β, IL-6, TNF-α, and IFN-γ ( Figure 5 A-5D). However, Cat@P-CD-PMNs were unable to eliminate anti-inflammatory cytokines ( Figure 5 E and Figure 5 F), which proved that it only has anti-inflammatory effect but no pro-inflammatory effect.

[0044] 7. Inflammatory chemotaxis of Cat@P-CD-PMNs: Schematic diagram and results of transwell migration experiment Figure 6 As shown, driven by the chemokine CXCL2, a large number of P-live PMNs entered the lower chamber from the upper chamber of the transport system. In contrast, the chemotactic effect of Cat@P-CD-PMNs on inflammation was also retained, and its chemotactic ability was comparable to that of live PBMCs. PMNs that died after paraformaldehyde fixation (PFA-PMNs) no longer had chemotactic ability because the chemical toxicity of paraformaldehyde destroyed the conformation and function of their chemokine receptors. These results show that the "freeze shock" technology can successfully preserve the structure and function of chemokine receptors of neutrophils, enabling them to accurately cross the capillary space and target inflammatory foci.

[0045] Example 3 Preparation of mouse-derived pre-activated cryo-shock neutrophils Cat@P-CD-PMNs Mouse-derived Cat@P-CD-PMNs were used in animal experiments. The preparation steps are as follows: PMNs were collected from the whole blood and spleen of ICR mice (6-week-old female) using a neutrophil extraction kit (P9040, Solebro). 1.5 mg kg −1 Lipopolysaccharide (LPS) was introduced into mice to activate neutrophils. After 6 hours, blood was collected from the eye sockets, and the spleen was removed and ground. 4 mL of reagent A was added to a centrifuge tube, and then 2 mL of reagent C was carefully superimposed on reagent A to form a gradient interface. The blood and spleen cells were pooled and spread above the surface of liquid C to keep the interface between the two liquid surfaces clear. Then centrifuged at 800 g, 4°C, for 25 min, and the neutrophils between reagent C and reagent A and in reagent A were aspirated into a 15 mL clean centrifuge tube.

[0046] S2. Add red blood cell lysis buffer to the sample to lyse red blood cells, wash with 1× PBS three times, suspend in universal serotype non-programmed freezing solution, precool at -80℃ for 20 min, and immerse in liquid nitrogen for 12 h; S3. Before use, thaw the cells stored in liquid nitrogen at 37°C and centrifuge at 250 g for 3 min. After washing with PBS solution (pH 7.4), remove the supernatant and collect the pre-activated cryo-shock neutrophils (P-CD-PMN). In the same way, unactivated cryo-shock neutrophils (CD-PMN) can be prepared; S4. P-CD-PMNs were suspended in a PBS solution containing catalase (Cat) (2 mg ml-1). After culturing for 2 hours, the culture medium was centrifuged at 300 g for 5 min, and the supernatant was removed to obtain Cat@P-CD-PMNs.

[0047] Example 4 Application of Cat@P-CD-PMNs in the treatment of sepsis The mouse sepsis model was induced by cecal ligation and puncture. Twelve hours later, each group of mice was intravenously injected with 200ul DiI-labeled Cat@P-0-PMNs (1.0×10 7 count mL -1 , 200 μL), Cat@CD-PMNs (1.0×10 7 count mL -1 ) or Cat@P-CD-PMNs (1.0×10 7 count mL -1). At 1 h, 6 h, and 12 h after injection, the fluorescence images of important organs after different treatments were recorded using the AniView100 multimodal live animal imaging system at an excitation wavelength of 549 nm. Figure 7 A and Figure 7 As shown in Figure B, Cat@P-0-PMNs and Cat@CD-PMNs have a certain targeting effect on inflammatory lesions. In contrast, Cat@P-CD-PMNs have good targeting ability and long-term residence effect on these inflammatory organs, which indicates that Cat@P-CD-PMNs can target inflammatory lesions and provide long-term treatment for sepsis.

[0048] Five groups were randomly established from healthy mice, one of which was a sham operation group (sham) and the other four groups were sepsis groups. 3 hours, 6 hours and 9 hours after the establishment of the CLP model, mice in the four sepsis groups were intravenously injected with PBS, P-CD-PMNs (Drug 1), catalase (Drug 2) and Cat@P-CD-PMNs (Drug 3) (once at each time point). 24 hours later, the levels of pro-inflammatory cytokines in the lung tissue of mice were detected ( Figure 7 C-7F) and the ROS levels in the main damaged organs (liver and lung) ( Figure 7 G-7I). Compared with the sham operation group, the mRNA expression levels of different pro-inflammatory cytokines (IL-1β, IL-6, TNF-α, and IFN-γ) in septic mice (after PBS treatment) were significantly increased, indicating that the injured organs of septic mice were in a state of hyperinflammation. Catalase and P-CD-PMNs led to a slight decrease in the expression of these pro-inflammatory cytokines. More importantly, Cat@P-CD-PMNs treatment significantly reduced the expression of these pro-inflammatory cytokines, strongly confirming the broad-spectrum anti-inflammatory effect of Cat@P-CD-PMNs in sepsis. By quantifying the ROS concentrations in liver and lung tissues using a dihydroethidium (DHE) probe, it was found that the ROS levels in both organs of mice treated with catalase and P-CD-PMNs were moderately reduced. Cat@P-CD-PMNs treatment effectively cleared almost all ROS, fully demonstrating its expected antioxidant capacity in sepsis.

[0049] Example 5 Application of Cat@P-CD-PMNs in the treatment of COVID-19 The mice were randomly divided into 5 groups, one of which was a sham operation group (sham), and the other 4 groups were treated with aerosol inhalation of the mouse coronavirus strain MHV-A59 to establish a COVID-19 alternative mouse model. On the first, third, and fifth days after the establishment of the mouse model, COVID-19 mice were intranasally injected with 30 μL PBS, P-CD-PMNs (Drug1), catalase (Drug2), and Cat@P-CD-PMNs (Drug3), respectively (once at each time point). On the fifth day after different treatments, the mice were killed, their lung tissues were isolated, and the concentrations of various proinflammatory cytokines and ROS were detected.

[0050] ELISA results Figure 8 As shown in A-8D, the concentrations of various proinflammatory cytokines (IFN-γ, IL-1β, IL-6, and TNF-α) in the lung tissue of COVID-19 mice (PBS group) were significantly increased compared with the sham group. The addition of P-CD-PMNs and catalase led to a moderate decrease in the levels of these proinflammatory cytokines, confirming the moderate anti-inflammatory properties of both drugs. In contrast, Cat@P-CD-PMNs treatment significantly reduced the concentrations of these proinflammatory cytokines in lung tissue, strongly demonstrating its broad-spectrum anti-inflammatory effect. Therefore, Cat@P-CD-PMNs has great potential in treating the cytokine storm caused by COVID-19.

[0051] The results of DHE staining of lung tissue are as follows Figure 8 As shown in Figure E, P-CD-PMNs and catalase can remove ROS to a certain extent, while Cat@P-CD-PMNs treatment significantly inhibited the accumulation of ROS in lung tissue, indicating that it has a strong antioxidant effect. More importantly, Figure 8 As shown in Figure 5(F), Cat@P-CD-PMNs treatment significantly reduced the mortality of COVID-19 mice, and the improvement in survival rate was significantly higher than that in the group treated with P-CD-PMNs and catalase alone, confirming its overall therapeutic effect.

[0052] Example 6 Application of Cat@P-CD-PMNs in the treatment of skin wounds On the first, third, and fifth days after the establishment of the mouse skin wound model, 80 μL of PBS, P-CD-PMNs, catalase, and Cat@P-CD-PMNs were sprayed on the wounds of each group of mice (once at each time point), and the wound area was monitored after different treatments. The results are shown in Figure 2. Fig. 9As shown in A. Compared with the PBS-treated group, the use of P-CD-PMNs or catalase moderately accelerated wound healing, while Cat@P-CD-PMNs treatment significantly increased the wound repair rate. Among them, after 12 days of different treatments, the wound area decreased by 68.80% (PBS), 76.58% (P-CD-PMNs), 75.56% (catalase), and 92.13% (Cat@P-CD-PMNs), respectively ( Fig. 9 B), fully demonstrated the superior ability of Cat@P-CD-PMNs to promote wound healing.

[0053] The DHE probe was used to measure the ROS level in the skin wound. Fig. 9 C. Compared with healthy skin tissue, ROS accumulated in the wound tissue (PBS group). After treatment with P-CD-PMNs or catalase, the ROS concentration in the wound tissue decreased to a certain extent. However, Cat@P-CD-PMNs can remove a large amount of ROS from the wound tissue. The ROS level after treatment is comparable to that observed in healthy skin, which strongly confirms its effective antioxidant activity. H&E staining results are shown in Fig. 9 As shown in D, compared with healthy skin, the wounds in the PBS-treated group had obvious inflammatory infiltration (characterized by infiltration of multiple immune cells) and extensive tissue necrosis. P-CD-PMNs or catalase treatment effectively reduced the extent of tissue necrosis, but had little improvement in inflammatory infiltration. Cat@P-CD-PMNs treatment significantly reduced tissue necrosis and inflammatory infiltration. More importantly, Cat@P-CD-PMNs significantly increased granulation tissue formation, epidermal recovery (continuous epithelial tissue appearance), skin hyperplasia, and the number of new hair follicles, indicating that wound repair has entered the proliferation and remodeling stage.

[0054] The above-described embodiments are only preferred embodiments for fully illustrating the present invention, and the protection scope of the present invention is not limited thereto. Equivalent substitutions or changes made by those skilled in the art based on the present invention are within the protection scope of the present invention. The protection scope of the present invention shall be subject to the claims.

Claims

1. A pre-activated cryo-shock neutrophil nanoparticle with anti-inflammatory and antioxidant functions, characterized in that: TNF-α pre-activated cryo-shock neutrophils are used as carriers and loaded with catalase; the TNF-α pre-activated cryo-shock neutrophils are neutrophils prepared by cryo-shock technology using TNF-α pre-activated neutrophils as raw materials.

2. The method for preparing the pre-activated cryo-shocked neutrophil nanoparticles according to claim 1, characterized in that: The steps include: S1. Obtain neutrophils; S2. Stimulate neutrophils with TNF-α to obtain pre-activated neutrophils; S3. performing cryo-shock on the cryo-fluid containing pre-activated neutrophils to obtain TNF-α pre-activated cryo-shock neutrophils; S4. The TNF-α pre-activated cryo-shocked neutrophils are co-incubated with a catalase solution to obtain TNF-α pre-activated cryo-shocked neutrophil nanoparticles loaded with catalase, i.e., the pre-activated cryo-shocked neutrophil nanoparticles having anti-inflammatory and antioxidant functions.

3. The preparation method according to claim 2, characterized in that: In step S2, the TNF-α stimulation of neutrophils is to use recombinant human TNF-α to stimulate neutrophils at 36 to 38° C. for 1 to 3 hours.

4. The preparation method according to claim 2, characterized in that: The freezing shock in step S3 is precooling at -75 to -85°C for 15 to 25 minutes and then freezing to death with liquid nitrogen and resuscitation.

5. The preparation method according to claim 4, characterized in that: The liquid nitrogen freezing in step S3 is performed by immersing in liquid nitrogen for 6 to 12 hours.

6. The preparation method according to claim 2, characterized in that: The concentration of catalase during the co-incubation in step S4 is 30 μg / cell.

7. Use of the pre-activated cryo-shock neutrophil nanoparticles with anti-inflammatory and antioxidant functions according to claim 1 in the preparation of therapeutic drugs for diseases requiring simultaneous anti-inflammatory and antioxidant treatments.

8. The use according to claim 7, characterized in that: The disease is sepsis, novel coronavirus infection or skin wound.

9. A preparation for anti-inflammatory and antioxidant treatment, characterized in that Contains the pre-activated cryo-shock neutrophil nanoparticles with anti-inflammatory and antioxidant functions as claimed in claim 1.

10. The preparation according to claim 9, characterized in that Pharmaceutically acceptable excipients are also included.